Liton

Quick links to important sections

Liton

Method of action: Laxative

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Liton

Quick Facts

Property Description
Active ingredient Bisacodyl
Form Enteric-coated tablets, Suppositories
Pharmacological class Stimulant Laxative
General purpose Temporary relief of sluggish bowel function
Origin Synthetic, Diphenylmethane derivative

Liton is a pharmaceutical preparation whose single active ingredient is Bisacodyl (INN), which is primarily classified as a Stimulant Laxative. The fundamental purpose of this medicine is to facilitate and initiate bowel movements in individuals experiencing temporary difficulty or infrequency in passing stool. It is generally positioned as an over-the-counter (OTC) option for short-term use.


What Type of Medicine is Liton?

Liton belongs to the diphenylmethane derivative class, recognized as a synthetic prodrug that must undergo metabolic activation within the colon to exert its effect. As a Stimulant Laxative, it actively affects the lower intestinal function. This mechanism is clinically recognized for providing a predictable response when addressing instances of occasional constipation, confirming its established role as an effective agent for bowel evacuation.

Composition and Physical Form

Liton is strictly a single-ingredient product, with Bisacodyl compounded into various forms for optimal delivery. The preparation is commonly available as enteric-coated tablets for the oral route of administration and as suppositories for the rectal route. The enteric coating is a critical design feature of the tablets, protecting the medicine from the high acidity of the stomach to ensure it reaches the large intestine intact, thereby allowing for the proper timing of its therapeutic effect.


General Purpose and Core Benefit

The core therapeutic purpose of Liton is to provide short-term relief by correcting the discomfort associated with infrequent or difficult bowel movements. Liton has a powerful local action in increasing intestinal motility. This means the medicine effectively aids the natural process by both stimulating movement and promoting the accumulation of fluid in the contents, thereby supporting the functional integrity of the lower digestive tract for temporary symptomatic management.

Regulatory References

  1. NIH MedlinePlus Drug Information - Bisacodyl

What side effects are possible with Liton?

Possible Side Effects and Safety Information

The safety profile of Liton (Bisacodyl) is structured around categories defined by government regulatory authorities, reflecting incidence rates from official reports and clinical data. Adverse reactions are primarily classified by frequency and the body system affected, with the most commonly reported effects involving the gastrointestinal tract.


Official Adverse Reaction Classification

The most frequently classified adverse events are primarily gastrointestinal disorders.

Frequency Classification Key Adverse Reactions
Common (affecting 1 in 100 to 1 in 10 users) Abdominal pain, Abdominal cramps, Diarrhoea, Nausea
Uncommon Vomiting, Dizziness, Haematochezia (blood in stool), Abdominal discomfort
Rare Syncope (fainting), Hypersensitivity, Angioedema, Anaphylactic reactions, Colitis (including ischaemic colitis)

Serious Adverse Reactions and Safety Constraints

Official regulatory documents note that rare, serious adverse reactions include severe hypersensitivity events such as anaphylaxis and angioedema, as well as reports of colitis. The official safety framework also highlights risks associated with duration of use.

Prolonged excessive use is formally documented as potentially leading to significant risks of fluid and electrolyte imbalance, specifically hypokalaemia (low potassium), and associated renal tubular damage. Safety restrictions define that the medicine is contraindicated in conditions such as intestinal obstruction, ileus, acute inflammatory bowel diseases, and severe dehydration. Furthermore, dizziness and syncope are often officially attributed to a vasovagal response related to abdominal spasm rather than a direct drug effect.

Safety considerations for special populations note that fluid loss may be particularly harmful in elderly patients and individuals with renal insufficiency.

Overdose and Emergency Response

Overdose and When to Seek Help

If you suspect an overdose involving Liton, treat the situation as a medical emergency and seek immediate, professional medical attention.

Official authoritative medical resources, including those maintained by major global health and regulatory bodies, currently do not contain specific published clinical guidelines or public safety information detailing the overdose presentation, symptoms, or recommended treatment protocols for a drug identified as Liton. This lack of available, established data means there is no documented profile of overdose signs, risk factors, or substance-specific emergency procedures to rely on.


Immediate Action Required

Due to the unknown risks and potential for serious adverse effects from any unverified or improperly used substance, the following universal emergency procedures should be followed immediately:

  • Call your local emergency medical services immediately. Do not wait for symptoms to worsen.
  • Remain calm and be prepared to provide information about the amount of Liton taken, when it was consumed, and any concurrent medications or substances.
  • If the individual is unconscious, having a seizure, or having difficulty breathing, initiate life-saving protocols if trained, or await emergency personnel.

Always prioritize rapid medical evaluation in cases of suspected overdose. Immediate assessment by a healthcare professional is crucial to manage any life-threatening complications that may arise.

Therapeutic Uses of Liton

Main Uses and Therapeutic Intent

Liton is a pharmacological treatment primarily indicated for the management of bipolar disorder. Its therapeutic role focuses on stabilizing mood fluctuations associated with this condition, specifically targeting the prevention and treatment of manic episodes. In clinical practice, it is utilized to reduce the intensity and frequency of mood swings, helping individuals maintain a more balanced emotional state.

Beyond bipolar disorder, Liton may be used as an augmentation therapy in cases of major depressive disorder. In this context, it is added to a primary antidepressant regimen when standard treatments alone have not provided an adequate response. It is also indicated for the long-term prevention of recurrent depressive cycles.

Benefits and Clinical Goals

The primary objective of treatment with Liton is the long-term stabilization of the patient's psychological well-being. The benefits of this stabilization include:

  • Reduction of Manic Symptoms: It helps decrease the severity of symptoms during a manic phase, such as hyperactivity, rapid speech, and decreased need for sleep.
  • Prevention of Relapse: One of the core benefits is its prophylactic effect, meaning it helps extend the periods of stability between mood episodes and reduces the likelihood of future hospitalizations.
  • Control of Mood Volatility: By acting on the central nervous system, it helps smooth out the extreme 'highs' and 'lows' that characterize affective disorders.
  • Support in Treatment-Resistant Depression: For individuals with persistent depressive symptoms, it may help improve the overall effectiveness of the therapeutic plan.

The medication is intended to support a broader management strategy aimed at improving the functional capacity and quality of life for individuals living with chronic mood conditions.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Liton?

This section outlines the officially documented eligibility and non-eligibility rules for Liton (Bisacodyl), strictly based on governmental regulatory information.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents (12–17 years) are approved for use. Children aged 6–11 years may use the medicine, often requiring medical supervision.
Populations for whom use is contraindicated Patients with gastrointestinal obstruction or ileus, severe dehydration, acute abdominal conditions (including appendicitis), acute inflammatory bowel diseases, or known hypersensitivity to any component.
Age-related eligibility rules Use is not recommended for children under 6 years. Older adults may use the medicine but require caution due to the risk of fluid loss and dehydration.
Pregnancy and lactation eligibility Use during pregnancy and lactation is permitted only on medical advice; for lactation, the active metabolite is not found in breast milk.

Eligibility-Related Restrictions

Eligibility is restricted for patients with conditions that pose a high risk of fluid and electrolyte imbalance. Specifically, treatment must be discontinued if fluid loss or dehydration occurs. Additionally, the oral formulation is restricted for patients with rare hereditary sugar intolerances (such as lactase deficiency or galactose/fructose intolerance) due to the presence of specific excipients.

What should I know about interactions with other medicines?

Liton’s official interaction profile is characterized by two primary concerns documented in regulatory labels: protecting the integrity of the enteric-coated tablet and managing pharmacodynamic risks related to electrolyte balance. The integrity of the tablet coating requires mandatory timing separation from specific substances to prevent premature dissolution, which could lead to gastric irritation.

Co-administration with Antacids and Proton Pump Inhibitors (PPIs) is restricted, and the tablet must be separated by at least one hour from these acid-reducing agents, as documented in regulatory labeling. Consumption of Milk or other Dairy Products must also be separated by at least one hour from the oral tablet.

Regarding pharmacodynamic effects, the regulatory basis identifies an increased risk when Liton is co-administered with other potassium-depleting medicines. Concomitant use with Diuretics or Adreno-corticosteroids, particularly if Bisacodyl is used in excessive doses, may lead to or exacerbate hypokalemia (low potassium levels). This hypokalemia risk is documented as having an indirect effect: it can increase patient sensitivity and toxicity to Cardiac Glycosides. Regulatory documents further note that co-administration with Other Laxatives may enhance gastrointestinal side effects.

Mechanism of Action

How Liton Works: Mechanism of Action

Liton's action involves the modulation of key enzymatic and signaling pathways primarily within the central nervous system. It functions as an enzyme inhibitor, chiefly targeting Inositol Monophosphatase (IMPase) and Glycogen Synthase Kinase-3 (GSK-3) inside nerve cells.

Inhibition of IMPase alters the phosphoinositide signaling cascade by affecting the turnover of key cellular messengers, thereby modulating the overall intensity of signaling within specific neural circuits. Concurrently, inhibition of GSK-3 regulates molecular processes linked to neuroplasticity and neuroprotection, contributing to the regulation of neurogenesis and the maintenance of synaptic connections.

Liton also acts as a neuromodulator and ion channel regulator, influencing the flux of charged particles across neuronal membranes. This multi-faceted action contributes to a more tonic and balanced release of neurotransmitters, which ultimately produces a shift toward a more consistent pattern of nerve cell firing.

Dosage and Administration Information

How to Use Liton: Administration Guidelines

Liton (Bisacodyl) is administered according to specific regimens for short-term, occasional use. The primary routes of administration are oral for systemic effect and rectal for local, rapid action. This dual approach offers flexibility in usage but is governed by dosing and administration constraints to ensure proper function.


Administration Scope

Feature Instruction
Route of Administration Oral (enteric-coated tablets); Rectal (suppositories).
Standard Adult Dose 5 mg to 15 mg oral or 10 mg rectal, as a single dose.
Timing and Frequency Once daily, as needed. Oral tablets are typically taken at bedtime for a morning effect. Rectal suppositories act within 15 to 60 minutes.
Course Duration Intended for short-term use only, not generally exceeding seven continuous days.

Administration Requirements

Strict adherence to specific preparation and timing is required for the oral dosage form. The enteric-coated tablets must be swallowed whole and should not be crushed, chewed, or broken, as this would compromise the protective coating. Furthermore, the tablets should not be taken within one hour of consuming substances that reduce stomach acidity, such as milk products or antacids. These procedural constraints are essential to ensure the medicine reaches the colon intact, where it is intended to act.

Age-Specific Usage

Standard instructions provide specific dosing rules based on age. For children aged 2 to under 10 years, a lower standard dose, often 5 mg, is specified. Children 10 years and older typically follow the standard adult dosing regimen (5 mg to 15 mg oral or 10 mg rectal) as a single, once-daily dose when needed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Liton

Evidence for Occasional and Idiopathic Constipation

Studies such as randomized controlled trials (RCTs) were used for clinical investigation to evaluate the agent compared to an inactive pill (placebo) in adult patients experiencing episodic constipation. Research explored how symptoms change over time and focused on outcomes related to physical discomfort. Specifically, studies monitored and measured changes in stool frequency, including complete, spontaneous bowel movements, and changes in stool consistency using standard scales.

Studies reported measurements of time to first bowel movement and the rate of subsequent movements over the short follow-up period in the observed populations. Research highlights changes measured during the study period in symptoms associated with straining. The evidence contributes to the broader landscape used by regulators to establish the medicine’s recognized role for temporary, symptomatic management of infrequent bowel movements.


Research for Bowel Evacuation Prior to Procedures

Liton was studied for its application in research contexts involving preparing the body for medical procedures. These studies did not evaluate the medicine alone but investigated it as one component within larger, multi-agent bowel cleansing regimens. Research monitored outcomes by tracking the quality of bowel preparation, assessing whether the colon lining is adequately cleared. Studies explored the agent's role as an adjunct component, observing that its contribution was dependent on the specific combination protocol used.


Duration of Evidence and Long-Term Follow-up

The majority of evidence used to establish the core findings for Liton is derived from short-term trials. For occasional constipation, follow-up durations were often limited to a matter of days or up to four weeks. Consequently, there is limited information for long-term outcomes describing the effects of prolonged, continuous use. Research does not determine whether an individual will respond similarly over extended periods, and long-term effects are not fully established.


What is Still Uncertain About the Research for Liton

The evidence highlights what is known—and what is still uncertain—about the medicine’s clinical profile. Primary research limitations include short follow-up durations and a lack of comparative evidence against many newer or alternative treatment options. Research focusing on the agent's role in managing chronic, sustained constipation is often limited, relying on its established position in clinical protocols rather than dedicated long-term RCTs.

Key Studies & References

  1. FDA Drug Labeling for Bisacodyl (Addressing Constipation and Bowel Preparation)

Frequently Asked Questions (FAQ)

Common questions about Liton (FAQ)

Q: What happens if I miss a dose of Liton?

Since Liton is intended for occasional, as-needed use to address temporary constipation, the official product information does not include specific 'missed dose' instructions. The product labeling suggests that a person may take the next single dose as needed, provided they do not exceed the daily limit. The primary caution is that the total amount defined by the label should not be exceeded within a 24-hour period.


Q: Can I take Liton if I am also on supplements like Vitamin D or magnesium?

Some forms of the Liton tablet contain magnesium as an inactive ingredient. Regulatory guidance often recommends a separation period, such as taking Liton two hours before or after other medications or supplements. This separation is suggested to help the enteric coating function correctly and to allow for the proper absorption of the other drug or supplement.


Q: How does Liton affect blood pressure or heart rate?

Official safety documents do not commonly report a direct effect of Liton on baseline blood pressure or heart rate. However, official safety summaries note that rare side effects like dizziness and temporary loss of consciousness (syncope) can occur. These effects are often attributed to a vasovagal response—a reflex triggered by abdominal cramps—which can temporarily affect circulation.


Q: Are there any official warnings about driving or operating machinery while on Liton?

Official documents suggest that individuals who experience severe abdominal spasm resulting in dizziness and/or syncope (fainting) consider avoiding driving or operating potentially hazardous machinery. Although formal studies on driving have not been performed, this precaution is based on the potential risk of temporary impairment from these side effects.


Q: Where can I find the official patient leaflet for Liton?

The official package insert, which includes detailed regulatory and safety information, can be located on government-run websites. These sources commonly include the FDA's DailyMed or the National Institutes of Health's MedlinePlus resources.


Q: Is Liton addictive or habit-forming?

Stimulant laxatives like Liton are not intended for continuous daily use. Official warnings emphasize that long-term, chronic use or misuse is described as potentially resulting in the body developing a dependence on the laxative to have a bowel movement. For this reason, the medicine is intended solely for temporary, occasional relief.


Q: What should I do if Liton doesn't seem to be working for me?

Regulatory documents contain clear warnings for when the medicine is ineffective. If a person fails to have a bowel movement after using the medicine, or if they find they need to use a laxative for more than one week, official product labeling advises stopping use under these circumstances. These events may be signs of a more serious underlying condition that requires attention.


Q: Can people with diabetes safely take Liton?

General eligibility for patients with diabetes is not directly addressed in the standard product labeling. However, the oral tablets are restricted for patients with rare hereditary sugar intolerances (such as lactase deficiency) due to some of the tablet's excipients. For individuals with pre-existing conditions like diabetes, regulatory guidance suggests consulting a health professional before use.


Q: Are there any known interactions with herbal remedies and Liton?

There is generally not enough official information to definitively confirm the absence of interactions with all complementary or herbal remedies. Due to the lack of specific studies, official sources maintain a position of caution, as these products are often not studied for interactions in the same way as approved prescription medications.


Q: What is the mechanism of action of Liton according to simple terms?

In simple terms, Liton is a Stimulant Laxative that works by causing two main actions in the large intestine. It helps the muscles in your intestines contract more forcefully to move contents along. It also helps the intestines release more water into the stool, which softens the stool for easier passage.


Q: Does research show a consistent effect of Liton across different patient groups?

Studies establishing the core findings for Liton primarily involved short-term trials focused on adult patients with occasional constipation. Official research summaries state that there is limited information to determine whether an individual will respond similarly over extended periods or if the effects are consistent across all patient populations, such as the elderly or children.


Q: Can Liton be taken with or without food?

The main restriction related to consumption concerns the enteric coating of the tablets. Official labeling states that the tablets should not be taken within one hour of consuming milk products or antacids. No general restrictions on other types of food are typically provided, but separation from the specific listed products is necessary to ensure the product functions as intended.


Q: Why do official sources say Liton 'is not recommended' for certain groups?

Official dosing guidelines state that Liton is generally not recommended for children under 6 years of age. This is a precautionary rule commonly applied to pharmaceutical products, reflecting the need for increased medical supervision and precise dosing requirements for this younger age group.


Q: What is the pregnancy safety category for Liton?

Official labeling advises that if a person is pregnant or breast-feeding, consultation with a health professional is advised before use. The standardized letter categories (such as A, B, or C) often assigned by regulatory agencies are typically not included in the consumer-facing product information for this over-the-counter medication.


Q: If I have kidney problems, can I still take Liton?

Official safety considerations highlight that fluid loss caused by the medicine may be particularly harmful in individuals with renal insufficiency (kidney problems). Due to this risk, regulatory bodies indicate that individuals with existing kidney issues should consult a health professional prior to using the medicine.


Q: What is the difference between Liton and other similar medicines?

Liton's active ingredient, Bisacodyl, is officially classified as a Stimulant Laxative. This classification is distinct from other laxative classes, such as bulk-forming or osmotic. This classification means the medicine is described as working by directly stimulating the nerves and muscles of the intestine to induce a bowel movement.


Q: When should I worry about a side effect from Liton?

Official 'Stop Use' warnings indicate that the medication should be discontinued immediately and professional care should be sought if a person experiences rectal bleeding or fails to have a bowel movement after use. Discontinuation is also advised if a person notices signs of a serious allergic reaction, such as swelling or hives.


Q: What are the official clinical trial results for Liton?

Clinical trials were conducted primarily to assess the medicine's effect in adult patients experiencing occasional constipation. Studies measured outcomes such as the time to first bowel movement, changes in stool frequency, and improvements in discomfort associated with straining. However, specific numerical results from these trials are typically not provided in the consumer-facing product summaries.


Q: Is there a risk of overdose with Liton?

Official labeling includes a warning against accidental overdose. In the event of an overdose, the warning advises contacting emergency services or a poison control center immediately. Taking high doses may result in adverse effects such as watery stools, abdominal cramps, and the loss of essential fluids and electrolytes.


Q: Is Liton a controlled substance?

According to official product information, Liton (Bisacodyl) is designated as an Over-the-Counter (OTC) medication. It is not classified as a controlled substance by the federal regulatory body.

How should Liton be stored and disposed of?

How to Store and Dispose of Liton

Official regulatory labeling for Liton (Bisacodyl) specifies precise conditions to maintain the product's quality and ensure safe handling.


Storage Conditions

Liton tablets must be stored at Controlled Room Temperature, which is 25 C (77 F), with permitted variations between 15 C and 30 C. All forms require protection from excessive humidity and must be kept in their original container. The tablets should also be protected from light. Suppositories must not exceed a storage temperature of 30 C; if they become soft, brief refrigeration is required to restore firmness before use.

  • Child Safety: All forms of Liton must be stored out of reach of children.

Disposal

Any unused or expired Liton product must be disposed of in accordance with local requirements. Disposal should follow established local pharmaceutical waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Liton found in:

A-Z Index: